| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
|
JAMA
|
2002
|
80.37
|
|
2
|
Long-term exposure to air pollution and incidence of cardiovascular events in women.
|
N Engl J Med
|
2007
|
14.90
|
|
3
|
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
12.44
|
|
4
|
Calcium plus vitamin D supplementation and the risk of fractures.
|
N Engl J Med
|
2006
|
12.09
|
|
5
|
Calcium plus vitamin D supplementation and the risk of colorectal cancer.
|
N Engl J Med
|
2006
|
8.73
|
|
6
|
The Women's Health Initiative recruitment methods and results.
|
Ann Epidemiol
|
2003
|
8.42
|
|
7
|
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.
|
Nat Genet
|
2009
|
7.30
|
|
8
|
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
|
JAMA
|
2010
|
7.12
|
|
9
|
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
6.51
|
|
10
|
Ethnicity and breast cancer: factors influencing differences in incidence and outcome.
|
J Natl Cancer Inst
|
2005
|
5.52
|
|
11
|
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.
|
Lancet
|
2009
|
5.22
|
|
12
|
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
|
Lancet
|
2011
|
5.21
|
|
13
|
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
|
JAMA
|
2008
|
4.42
|
|
14
|
Projecting individualized absolute invasive breast cancer risk in African American women.
|
J Natl Cancer Inst
|
2007
|
3.93
|
|
15
|
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women.
|
J Natl Cancer Inst
|
2008
|
3.73
|
|
16
|
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.
|
Am J Epidemiol
|
2009
|
3.33
|
|
17
|
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.
|
JAMA
|
2006
|
3.29
|
|
18
|
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study.
|
Am J Epidemiol
|
2008
|
3.05
|
|
19
|
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
2.97
|
|
20
|
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.
|
Am J Epidemiol
|
2008
|
2.79
|
|
21
|
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.
|
JAMA
|
2011
|
2.70
|
|
22
|
Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts.
|
Arch Intern Med
|
2009
|
2.54
|
|
23
|
Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.
|
J Natl Cancer Inst
|
2013
|
2.45
|
|
24
|
Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial.
|
J Natl Cancer Inst
|
2007
|
2.37
|
|
25
|
Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
|
J Natl Cancer Inst
|
2007
|
2.36
|
|
26
|
Selecting differentially expressed genes from microarray experiments.
|
Biometrics
|
2003
|
2.34
|
|
27
|
Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women.
|
Cancer Res
|
2008
|
2.24
|
|
28
|
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
|
J Clin Oncol
|
2011
|
2.00
|
|
29
|
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.
|
Ann Intern Med
|
2014
|
1.87
|
|
30
|
Statistical issues arising in the Women's Health Initiative.
|
Biometrics
|
2005
|
1.72
|
|
31
|
Efficacy of exercise for menopausal symptoms: a randomized controlled trial.
|
Menopause
|
2014
|
1.67
|
|
32
|
Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
|
Am J Epidemiol
|
2006
|
1.54
|
|
33
|
Bead-based ELISA for validation of ovarian cancer early detection markers.
|
Clin Cancer Res
|
2006
|
1.52
|
|
34
|
Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women.
|
J Natl Cancer Inst
|
2011
|
1.51
|
|
35
|
The women's health initiative: lessons learned.
|
Annu Rev Public Health
|
2008
|
1.50
|
|
36
|
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.
|
J Clin Oncol
|
2012
|
1.48
|
|
37
|
Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.
|
Menopause
|
2014
|
1.44
|
|
38
|
Efficacy of yoga for vasomotor symptoms: a randomized controlled trial.
|
Menopause
|
2014
|
1.44
|
|
39
|
Potential role of HE4 in multimodal screening for epithelial ovarian cancer.
|
J Natl Cancer Inst
|
2011
|
1.39
|
|
40
|
Changing concepts: Menopausal hormone therapy and breast cancer.
|
J Natl Cancer Inst
|
2012
|
1.39
|
|
41
|
Heart rate variability, ambient particulate matter air pollution, and glucose homeostasis: the environmental epidemiology of arrhythmogenesis in the women's health initiative.
|
Am J Epidemiol
|
2009
|
1.34
|
|
42
|
Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial.
|
J Natl Cancer Inst
|
2010
|
1.31
|
|
43
|
Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network.
|
Menopause
|
2014
|
1.31
|
|
44
|
Effects of blood collection conditions on ovarian cancer serum markers.
|
PLoS One
|
2007
|
1.27
|
|
45
|
Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.
|
Clin Cancer Res
|
2008
|
1.23
|
|
46
|
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
|
Gynecol Oncol
|
2009
|
1.18
|
|
47
|
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.16
|
|
48
|
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
|
JAMA
|
2013
|
1.07
|
|
49
|
The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment.
|
J Natl Cancer Inst
|
2011
|
1.03
|
|
50
|
Ambient fine particulate matter exposure and myocardial ischemia in the Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative (EEAWHI) study.
|
Environ Health Perspect
|
2009
|
1.03
|
|
51
|
Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women.
|
Cancer Prev Res (Phila)
|
2011
|
1.00
|
|
52
|
Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects.
|
Breast Cancer Res
|
2014
|
0.95
|
|
53
|
Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers.
|
Cancer Biomark
|
2006
|
0.89
|
|
54
|
The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative.
|
Nutr Cancer
|
2008
|
0.87
|
|
55
|
Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.
|
Obstet Gynecol
|
2013
|
0.86
|
|
56
|
Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage.
|
Cancer Causes Control
|
2014
|
0.85
|
|
57
|
Women's health initiative view of estrogen avoidance and all-cause mortality.
|
Am J Public Health
|
2013
|
0.84
|
|
58
|
Optimal cutoffs of obesity measures in relation to cancer risk in postmenopausal women in the Women's Health Initiative Study.
|
J Womens Health (Larchmt)
|
2015
|
0.82
|
|
59
|
Use of alternative time scales in Cox proportional hazard models: implications for time-varying environmental exposures.
|
Stat Med
|
2012
|
0.82
|
|
60
|
Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use.
|
Clin Breast Cancer
|
2006
|
0.82
|
|
61
|
Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.
|
Gynecol Oncol
|
2009
|
0.78
|
|
62
|
Ovarian cancer biomarker screening: still too early to tell.
|
Womens Health (Lond Engl)
|
2010
|
0.78
|
|
63
|
Progestins and recurrence in breast cancer survivors.
|
J Natl Cancer Inst
|
2005
|
0.77
|
|
64
|
Migraine history, nonsteroidal anti-inflammatory drug use, and risk of postmenopausal endometrial cancer.
|
Horm Cancer
|
2012
|
0.77
|
|
65
|
Breast tenderness after initiation of conjugated equine estrogens and mammographic density change.
|
Breast Cancer Res Treat
|
2011
|
0.76
|
|
66
|
Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
|
Obstet Gynecol
|
2015
|
0.76
|
|
67
|
Concerns about published data from the estrogen-progestin (HT) arm of the WHI.
|
Am J Obstet Gynecol
|
2005
|
0.75
|
|
68
|
Prentice et al. Respond to "Studying Co-Occurrence of Multiple Outcomes".
|
Am J Epidemiol
|
2020
|
0.75
|
|
69
|
Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials.
|
Am J Epidemiol
|
2020
|
0.75
|